Acronym: E-Rare 2
Period: October 2010 till September 2014
Status: Completed
|
|
| Institutes (16) |
Top |
- Fonds National de la Recherche Scientifique (FNRS), more
- Ministry of development; General Secretariat for Research and Innovation (GSRT), more
- Ministério da Ciência e da Tecnologia; Foundation for Science and Technology (FCT), more
- Scientific and Technological Research Council of Turkey (TÜBITAK), more
- Institut National de la Santé et de la Recherche Médicale (INSERM), more
- French National Research Agency (ANR), more
- Federal Ministry of Education and Research (BMBF), more
- Ministry of health; Chief Scientist Office (CSO), more
- German Aerospace Centre; Project Management Agency on Environment, Culture & Sustainability (DLR), more
- Ministry of Health; Hellenic Centre for Disease Control & Prevention (HCDCP), more
- Spanish Ministry of Economy and Competiveness; Instituto de Salud Carlos III (ISCIII), more
- Ministry of health; The National Institute of Health Dr. Ricardo Jorge (INSA), more
- National Institute of Health (ISS), more
- National Centre for Research and Development (NCBiR), more
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Nederlandse organisatie voor gezondheidsonderzoek en zorginnovatie (ZonMw), more
- University of Pecs (UNI PECS), more
|
| Abstract |
The E-Rare-2 project aims at deepening and extending the cooperation among the E-Rare-1 and the four new partners by :
- systematic exchange of information,
- yearly launching of joint calls,
- thorough assessment of the funding mechanisms and results of the funded research projects,
- strategic activities aiming at a sustainable development and extension of the network.
Special attention will be given to the outreach and knowledge exchange with new member states, countries outside of Europe and key stakeholders/initiatives important for rare diseases.
E-Rare-2 activities will thus further contribute to reducing fragmentation of research and resources through the enhanced coordination and transnational funding of excellent research on rare diseases, thereby shaping the European Research Area for rare diseases. |
|
